On May 19, 2021, Shawn Guertin, member of the Board of Directors (the "Board") of DaVita Inc. (the "Company"), notified the Board that he will step down from the Board, as a member and chair of the Audit Committee of the Board (the "Audit Committee") and as a member of the Nominating and Governance Committee of the Board (the "Nominating and Governance Committee") due to anticipated increased time commitments associated with his pending new position as executive vice president and chief financial officer of CVS Health. Mr. Guertin therefore will no longer be considered a director nominee for the purposes of the election of directors at the Company's 2021 Annual Meeting of Stockholders to be held on June 10, 2021. Mr. Guertin's decision to step down is not the result of any disagreement with the Company and was effective as of May 19, 2021. In connection with the foregoing, the Board approved a reduction in the size of the Board from nine to eight members. Barbara Desoer, member of the Board and Compliance and Quality Committee of the Board (the "Compliance and Quality Committee"), and chair of the Compensation Committee of the Board (the "Compensation Committee"), was appointed to serve as a member of the Audit Committee and will no longer serve on the Compliance and Quality Committee. Paula Price, member of the Board, Compliance and Quality Committee and Audit Committee was appointed to serve as chair of the Audit Committee. John Nehra, member of the Board, Compensation Committee and Audit Committee, was appointed to serve on the Nominating and Governance Committee. All of the actions described in this paragraph were effective as of May 19, 2021.